{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000458","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.169310+00:00","generated_at":"2026-06-20T18:24:45.111975+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Heron reports preliminary FY2022 revenue $106.7M (+24% YoY); oncology franchise beats guidance","bullets":["Preliminary full-year 2022 net product sales $106.7M, up 24% YoY; oncology franchise $96.6M vs guidance $93-95M.","Q4 2022 ZYNRELEF net sales ~$3.8M, up 40% vs Q3; demand units 20,765 (+38%).","Full-year 2023 oncology franchise guidance $99-103M; APONVIE launch expected Q1 2023.","sNDA for expanded ZYNRELEF indication submitted to FDA Dec 2022; 10-month action date.","NOPAIN Act provides separate CMS reimbursement for ZYNRELEF through Dec 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000458","json":"https://secwatch.observer/filing/0000950170-23-000458.json","markdown":"https://secwatch.observer/filing/0000950170-23-000458.md","text":"https://secwatch.observer/filing/0000950170-23-000458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/0000950170-23-000458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/hrtx-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:24:45.111975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5236eee2d196f9b83e003b64b0c22906779f8118","claim":"HERON THERAPEUTICS, INC. /DE/ reported Three and twelve months ended December 31, 2022 results: revenue The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont.","evidence_excerpt":"On January 9, 2023, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its preliminary financial results for the three and twelve months ended December 31, 2022 (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/0000950170-23-000458-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three and twelve months ended December 31, 2022"},{"label":"Revenue","value":"The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}